Radiant Research/Clinical Research Advantage, Inc. Enrolls More Than 8,000 Subjects For Hepatitis B Vaccine Study

TEMPE, Ariz.--(BUSINESS WIRE)--Radiant Research/Clinical Research Advantage (Radiant/CRA), the country’s largest wholly owned clinical trial site management organization, has completed enrollment for the Dynavax Technologies Corporation (Dynavax) phase III clinical trial of HEPLISAV-B™, an investigational adult hepatitis B vaccine. 100 percent of the study was awarded to Radiant/CRA. Forty Radiant/CRA Sites are conducting the trial, which has randomized over 8,250 adults, including over 1,100 diabetic subjects. The sites completed the enrollment three months ahead of schedule without the use of an outside recruiting company.

Help employers find you! Check out all the jobs and post your resume.